交易 Immunovant Inc - IMVT 差价合约

交易条件

• 类型: 差价合约
• 点差: 0.13
• 长仓隔夜仓息调整: -0.02154%
• 短仓隔夜仓息调整: -0.00068%
• 隔夜调整仓息时间: 22:00 (UTC)
• 货币: USD
• 最低成交量: 1
• 保证金: 50.00%
• 证券交易所: United States of America
• 交易佣金: 0%
• 保证止损溢价: 1%

主要统计数据

• 前收盘价: 26.96
• 开仓: 26.29
• 1 年变化: 29.38%
• 日区间: 26.29 - 27.78

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.